Tg Therapeutics (TGTX) Cash from Financing Activities (2011 - 2026)

Tg Therapeutics' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $390.8 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 6504.93% year-over-year to $390.8 million in Q1 2026; TTM through Mar 2026 was $307.2 million, a 150.95% increase from a year earlier, with the FY2025 full-year figure at -$89.7 million, down 169.81% from the prior year.
• Cash from Financing Activities rose to $390.8 million in Q1 2026 per TGTX's latest filing, from $1.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $390.8 million in Q1 2026 and bottomed at -$78.2 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is $135000.0 (2022), against an average of $29.5 million.
• Across the five-year window, Cash from Financing Activities surged 34749.63% in 2023 and plunged 607100.0% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $49000.0 in 2022, then plunged by 102.04% to -$1000.0 in 2023, then plunged by 607100.0% to -$6.1 million in 2024, then jumped by 117.42% to $1.1 million in 2025, then surged by 36840.36% to $390.8 million in 2026.
• Per Business Quant, the three latest TGTX Cash from Financing Activities figures stand at $390.8 million (Q1 2026), $1.1 million (Q4 2025), and -$78.2 million (Q3 2025).